Corrigendum to "The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro" [Cancer Lett., 364, (2015), 142-155] Doi: 10.1016/j.canlet.2015.05.004;The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro

Cancer Letters

Volumn 364, Issue 2, 2015, Pages 142-155

  Piskareva, Olga ^a,b   Harvey, Harry ^a,b   Nolan, John ^a,b   Conlon, Ross ^a,b   Alcock, Leah ^a   Buckley, Patrick ^c   Dowling, Paul ^d   Henry, Michael ^e   O'Sullivan, Finbarr ^e   Bray, Isabella ^a,b   Stallings, Raymond L ^a,b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c BEAUMONT HOSPITAL   (Ireland)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^e DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Cisplatin; Drug resistance; Epithelial to mesenchymal transition (EMT); Invasion; Neuroblastoma; Proteomics

Indexed keywords

ALPHA ACTININ 4; CARRIER PROTEINS AND BINDING PROTEINS; CISPLATIN; ETOPOSIDE; INTEGRIN LINKED KINASE; IRINOTECAN; PROTEIN MYH9; PROTEIN ROCK1; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ACTIN FILAMENT; ARTICLE; CANCER RESISTANCE; CELL FUNCTION; CELL JUNCTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA MODIFICATION; EPITHELIAL MESENCHYMAL TRANSITION; IN VITRO STUDY; MASS SPECTROMETRY; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CHILD; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; INFANT; KIDNEY NEOPLASMS; MALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CHANDIPURA VIRUS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHILD; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; INFANT; KIDNEY NEOPLASMS; MALE; NEOPLASM PROTEINS; NEUROBLASTOMA; PROTEOMICS;

EID: 84930083699     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.09.010     Document Type: Erratum

References (63)

1. Davidoff A.M. Neuroblastoma. Semin. Pediatr. Surg 2012, 21(1):2-14.
2. Yu A.L., et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med 2010, 363:1324-1334.
3. London W.B., et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group Project. J. Clin. Oncol 2011, 29:3286-3292.
4. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
5. Harvey H., et al. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Int. J. Cancer 2014, 136:1579-1588.
6. Buckley P.G., et al. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin. Cancer Res 2010, 16(11):2971-2978.
7. Shen D.-W., et al. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev 2012, 64(3):706-721.
8. Lee J.M., et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol 2006, 172(7):973-981.
9. Lim J., Thiery J.P. Epithelial-mesenchymal transitions: insights from development. Development 2012, 139(19):3471-3486.
10. Toll A., et al. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases. J. Dermatol. Sci 2013, 72(2):93-102.
11. Lauffenburger D.A., Horwitz A.F. Cell migration: a physically integrated molecular process. Cell 1996, 84(3):359-369.
12. Rath N., Olson M.F. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep 2012, 13(10):900-908.
13. Vicente-Manzanares M., et al. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat. Rev. Mol. Cell Biol 2009, 10:778-790.
14. Totsukawa G., et al. Distinct roles of MLCK and ROCK in the regulation of membrane protrusions and focal adhesion dynamics during cell migration of fibroblasts. J. Cell Biol 2004, 164:427-439.
15. Prochazka P., et al. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers. Oncol. Rep 2013, 29(6):2415-2421.
16. Zheng X., et al. Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics. Cell Death Dis 2013, 4:e740.
17. Flahaut M., et al. Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region. Genes Chromosomes Cancer 2006, 45:495-508.
18. Kotchetkov R., et al. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int. J. Cancer 2003, 104:36-43.
19. Michaelis M., et al. Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. Cancer Lett 2007, 250:107-116.
20. Chen Y., et al. Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J. Pediatr. Surg 2012, 47:1797-1805.
21. Baskin F., Rosenberg R.N., Dev V. Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:3654-3658.
22. Urban A., et al. A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 2005, 5:796-804.
23. Keshelava N., et al. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998, 58:5396-5405.
24. Johnson S.W., et al. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997, 57:850-856.
25. Johnson S.W., et al. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp. Cell Res 1996, 226:133-139.
26. Kuroda H., et al. Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy. Int. J. Cancer 1991, 47:732-737.
27. Bagatell R., et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J. Clin. Oncol 2011, 29(2):208-213.
28. Michaelis M., et al. Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells. Mol. Cancer 2009, 8:80.
29. Michaelis M., et al. Chemotherapy-associated angiogenesis in neuroblastoma tumors. Am. J. Pathol 2012, 180:1370-1377.
30. Bedrnicek J., et al. Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Neoplasma 2005, 52:415-419.
31. Zhang J.T., Liu Y. Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat. Rev 2007, 33:741-756.
32. D'Aguanno S., et al. New insights into neuroblastoma cisplatin resistance: a comparative proteomic and meta-mining investigation. J. Proteome Res 2011, 10:416-428.
33. Verrills N.M., et al. Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J. Biol. Chem 2003, 278:45082-45093.
34. Satelli A., Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci 2011, 68(18):3033-3046.
35. Fortier A.M., Asselin E., Cadrin M. Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation. J. Biol. Chem 2013, 288(16):11555-11571.
36. Nozato M., et al. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma. Int. J. Oncol 2013, 42:134-140.
37. Arumugam T., et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009, 69:5820-5828.
38. Tan T.Z., et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol. Med 2014, 6(10):1279-1293.
39. Sánchez-Tilló E., et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell. Mol. Life Sci 2012, 69:3429-3456.
40. Puisieux A., Brabletz T., Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell Biol 2014, 16:488-494.
41. Taube J.H., et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(35):15449-15454.
42. Shirakihara T., Saitoh M., Miyazono K. Differential regulation of epithelial and mesenchymal markers by δEF1 proteins in epithelial-mesenchymal transition induced by TGF-β. Mol. Biol. Cell 2007, 18(9):3533-3544.
43. Guaita S., et al. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J. Biol. Chem 2002, 277(42):39209-39216.
44. Dave N., et al. Functional cooperation between snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition. J. Biol. Chem 2011, 286(14):12024-12032.
45. Casas E., et al. Snail2 is an essential mediator of twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res 2011, 71(1):245-254.
46. Tran D.D., et al. Temporal and spatial cooperation of snail1 and twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol. Cancer Res 2011, 9(12):1644-1657.
47. Guha M., Zhou M., Wang Y.L. Cortical actin turnover during cytokinesis requires myosin II. Curr. Biol 2005, 15:732-736.
48. Murthy K., Wadsworth P. Myosin-II-dependent localization and dynamics of F-actin during cytokinesis. Curr. Biol 2005, 15:724-731.
49. Betapudi V. Myosin II motor proteins with different functions determine the fate of lamellipodia extension during cell spreading. PLoS ONE 2010, 5:e8560.
50. Aguilar-Cuenca R., Juanes-García A., Vicente-Manzanares M. Myosin II in mechanotransduction: master and commander of cell migration, morphogenesis, and cancer. Cell. Mol. Life Sci 2014, 71:479-492.
51. Lynch J., et al. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway. Carcinogenesis 2012, 33(5):976-985.
52. Sahai E., Marshall C.J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol 2003, 5(8):711-719.
53. Otey C., Carpen O. α- actinin revisited: a fresh look at an old player. Cell Motil. Cytoskeleton 2004, 111(February):104-111.
54. Sjöblom B., Salmazo A., Djinović-Carugo K. Alpha-actinin structure and regulation. Cell. Mol. Life Sci 2008, 65(17):2688-2701.
55. Hsu K.S., Kao H.Y. Alpha-actinin 4 and tumorigenesis of breast cancer. Vitam. Horm 2013, 93:323-351.
56. Yoshii H., et al. Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer. Oncol. Rep 2013, 30:1073-1080.
57. Honda K., et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 2005, 128:51-62.
58. Yamamoto S., et al. Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod. Pathol 2007, 20:1278-1285.
59. Barbolina M., et al. Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma. Lab. Invest 2008, 88:602-614.
60. Quick Q., Skalli O. a-Actinin 1 and a-actinin 4: contrasting roles in the survival, motility, and RhoA signaling of astrocytoma cells. Exp. Cell Res 2010, 316:1137-1147.
61. Nikolopoulos S.N., et al. The human non-muscle alpha-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells. Oncogene 2000, 19:380-386.
62. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29(34):4741-4751.
63. Li C.J., Li R.W., Wang Y.H., Elsasser T.H. Pathway analysis identifies perturbation of genetic networks induced by butyrate in a bovine kidney epithelial cell line. Funct. Integr. Genomics 2007, 7:193-205. 10.1007/s10142-006-0043-2.